If you've read this far, you understand what most of the market hasn't: the heart has been speaking in a language no instrument could read — until now. Every device before AuraSonics listened for a signal; we are built to capture the whole field. We're looking for a small number of early believers — investors, cardiologists, and advisors — to help convert a protected breakthrough into a utility-patent portfolio and a working prototype.
Request the investor briefing and access to the data room. Begin with the ring-fenced patent-conversion tranche, or explore the full seed round.
Request the briefing →Cardiologists, regulatory, signal-processing, sensor-engineering, and AI/ML leaders: help shape the bench. The advisory roles are being formed now.
Join the conversation →Serious prospective investors may be connected directly with our patent counsel at Wilson Sonsini to discuss the portfolio before committing.
Arrange a call →Tell us who you are and what you'd like to see. We respond personally — usually within a day. Conversations can proceed under NDA on request.
Your inquiry goes directly to the founder. Nothing is shared without your consent.
Available to speak with serious prospective investors about the AuraSonics patent portfolio. Introductions arranged on request.
AuraSonics, Inc. is a development-stage company. This page is for informational purposes only and does not constitute an offer to sell, or the solicitation of an offer to buy, any security; any such offer will be made only to qualified investors pursuant to definitive offering documents. The technology described across this site is the subject of pending provisional patent applications, has not been clinically validated, and is not FDA-cleared.